Karen Wilson Net Worth

The estimated Net Worth of Karen J Wilson is at least $6.1 Milión dollars as of 11 May 2018. Ms. Wilson owns over 3,760 units of Vaxart Inc stock worth over $14,812 and over the last 16 years she sold VXRT stock worth over $6,080,413. In addition, she makes $0 as Independent Director at Vaxart Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Wilson VXRT stock SEC Form 4 insiders trading

Karen has made over 19 trades of the Vaxart Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently she sold 3,760 units of VXRT stock worth $620,400 on 11 May 2018.

The largest trade she's ever made was exercising 36,993 units of Vaxart Inc stock on 11 January 2012 worth over $1,015,828. On average, Karen trades about 2,563 units every 49 days since 2009. As of 11 May 2018 she still owns at least 15,757 units of Vaxart Inc stock.

You can see the complete history of Ms. Wilson stock trades at the bottom of the page.

Karen Wilson biography

Karen J. Wilson serves as Independent Director of the Company. She is currently the Senior Vice President, Finance of Jazz Pharmaceuticals plc (“Jazz Pharmaceuticals”). She previously served as Vice President, Finance and Principal Accounting Officer of Jazz Pharmaceuticals and its predecessor company (Jazz Pharmaceuticals, Inc.) beginning in 2011. Ms. Wilson currently is also an independent Director for Angion Biomedica Board of Directors since April 2020. From 2009 to January 2011, she served as Vice President of Finance and Principal Accounting Officer at PDL BioPharma, Inc., a biotechnology company. From 2005 to 2009, she served as a principal at the consulting firm Wilson Crisler LLC. Prior to that, from 2001 to 2004, she was Chief Financial Officer of ViroLogic, Inc., a biosciences company. Prior to joining ViroLogic, Ms. Wilson served as Chief Financial Officer and Vice President of Operations for Novare Surgical Systems, Inc. from 1999 to 2001. Prior to 1999, Ms. Wilson worked for Deloitte & Touche LLP for ten years, serving clients in both the life sciences and technology fields. Ms. Wilson is a Certified Public Accountant in the State of California and received a B.S. in Business from the University of California, Berkeley.

How old is Karen Wilson?

Karen Wilson is 57, she's been the Independent Director of Vaxart Inc since 2020. There are 8 older and 5 younger executives at Vaxart Inc. The oldest executive at Vaxart Inc is Anne VanLent, 72, who is the Independent Director.

What's Karen Wilson's mailing address?

Karen's mailing address filed with the SEC is C/O VAXART, INC., 170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Vaxart Inc

Over the last 7 years, insiders at Vaxart Inc have traded over $322,706,538 worth of Vaxart Inc stock and bought 8,979,091 units worth $2,899,807 . The most active insiders traders include Capital, Llc Armistice Capi..., Steven Lo a Wouter Latour. On average, Vaxart Inc executives and independent directors trade stock every 57 days with the average trade being worth of $1,309,363. The most recent stock trade was executed by W. Mark Watson on 18 June 2024, trading 20,000 units of VXRT stock currently worth $13,600.

What does Vaxart Inc do?

since its founding in 2004, vaxart has pursued a vision of advancing vaccines—to make them as tablets rather than injections. the company’s proprietary oral vaccine delivery platform is suitable to deliver any recombinant vaccine, positioning vaxart to introduce oral forms of multiple vaccines in the rapidly growing global vaccines market.

Complete history of Ms. Wilson stock trades at Jazz Pharmaceuticals plc, PDL Biopharma Inc a Vaxart Inc

Vaxart Inc executives and stock owners

Vaxart Inc executives and other stock owners filed with the SEC include:

• Wouter Latour,
  Chairman of the Board
• Cezar Andrei Floroiu M.B.A.,
  CEO, Pres, Principal Financial Officer & Director
• Dr. Sean N. Tucker,
  Sr. VP & Chief Scientific Officer
• Margaret A. Echerd,
  Sr. VP & Principal Accounting Officer
• Sean Tucker,
  Chief Scientific Officer
• Margaret Echerd,
  Principal Accounting Officer, Vice President, Controller
• Anne VanLent,
  Independent Director
• Michael Finney,
  Independent Director
• Robert Yedid,
  Lead Independent Director
• Todd Davis,
  Independent Director
• Karen Wilson,
  Independent Director
• Keith Maher,
  Director
• Steven Boyd,
  Director
• Andrei Floroiu,
  Chief Executive Officer, Principal Financial Officer, Director
• Edward B. Berg,
  Sr. VP & Gen. Counsel
• John M. Harland M.B.A., CPA,
  Consultant
• Dr. James F. Cummings M.D.,
  Chief Medical Officer
• Dr. Rajesh Kapoor Ph.D.,
  Sr. VP of Quality
• Dr. Richard M. Schwartz,
  Sr. VP of Technical Operations
• Brant Biehn,
  Sr. VP of Bus. Operations
• Shaily Jaini Garg,
  Sr. VP of Clinical Devel. & Project Management
• Julie M Cherrington,
  Director
• Edward B Berg,
  SVP, General Counsel
• John M Harland,
  Chief Financial Officer
• Richard J Markham,
  Director
• Geoffrey F Cox,
  Director
• John P Richard,
  Director
• Phillip E Lee,
  Chief Financial Officer
• David E. Wheadon,
  Director
• James F. Cummings,
  Chief Medical Officer
• W. Mark Watson,
  Director
• Elaine J Heron,
  Director
• Steven Lo,
  President, Chief Exec Officer
• Fuad Ahmad,
  Interim CFO